Advertisement

AAPS PharmSci

, Volume 5, Issue 4, pp 41–48 | Cite as

Hydroxyzine from topical phospholipid liposomal formulations: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model

  • Abeer A W Elzainy
  • Xiaochen Gu
  • F. Estelle R. Simons
  • Keith J. SimonsEmail author
Article

Abstract

Hydroxyzine, an effective but sedating H1-antihistamine is given orally to treat allergic skin disorders. This study was performed to assess the peripheral H1-antihistaminic activity and extent of systemic absorption of hydroxyzine from liposomes applied to the skin. Using L-α-phosphatidylcholine (PC), small unilamellar vesicles (SUVs) and multilamellar vesicles (MLVs) containing hydroxyzine were prepared. Hydroxyzine in Glaxal Base (GB) was used as the control. Using a randomized, crossover design, each formulation, containing 10 mg of hydroxyzine, was applied to the shaved backs of 6 rabbits (3.08±0.05 kg). Histamine-induced wheal tests and blood sampling were performed at designated time intervals up to 24 hours. Compared with baseline, hydroxyzine from all formulations significantly suppressed histamine-induced wheal formation by 75% to 95% for up to 24 hours. Mean maximum suppression, 85% to 94%, occurred from 2 to 6 hours, with no differences among the formulations. The areas of plasma hydroxyzine concentration versus time area under the curve (AUCs) from PC-SUV and PC-MLV, 80.1±20.8 and 78.4±33.9 ng/mL/h, respectively, were lower than that from GB, 492±141 ng/mL/h (P<.05) over 24 hours. Plasma concentrations of cetirizine arising in-vivo as the active metabolite of hydroxyzine, from PC-SUV, PC-MLV, and GB, were similar with AUCs of 765±50, 1035±202, and 957±227 ng/mL/h, respectively (P<.05). Only 0.02% to 0.06% of the initial hydroxyzine dose remained on the skin after 24 hours. In this model, hydroxyzine from SUV and MLV had excellent topical H1-antihistaminic activity, and minimal systemic exposure occurred. Cetirizine formed in-vivo contributed to some of H1-antihistaminic activity.

Keywords

hydroxyzine L-α-phosphatidylcholine liposomes antihistamine skin rabbit 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Simons FER. H1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999;83:481–488.PubMedCrossRefGoogle Scholar
  2. 2.
    Reynolds JEF. Martindale the Extra Pharmacopoeia. 30th ed. London, UK: The Pharmaceutical Press, 1993.Google Scholar
  3. 3.
    El Maghraby GMM, Williams AC, Barry BW. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm. 2000;196:63–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Ganesan MG, Weiner ND, Flynn GL, Ho NFH. Influence of liposomal drug entrapment on percutaneous absorption. Int J Pharm. 1984;20:139–154.CrossRefGoogle Scholar
  5. 5.
    Niemiec SM, Latta JM, Ramachandran C, Weiner ND, Roessler BJ. Perifollicular transgenic expression of human Interleukin-1 receptor antagonist protein following topical application of novel liposome-plasmid DNA formulation in-vivo. J Pharm Sci. 1997;86:701–708.PubMedCrossRefGoogle Scholar
  6. 6.
    Fleisher D, Niemiec SM, Oh CK, Hu Z, Ramachandran C, Weiner N. Topical delivery of growth hormone releasing peptide using liposomal systems: an in-vitro study using hairless mouse skin. Life Sci. 1995;57:1293–1297.PubMedCrossRefGoogle Scholar
  7. 7.
    Egbaria K, Ramachandran C, Kittayanond D, Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by invitro diffusion studies. Antimicrob Agents Chemother. 1990;34:107–110.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Mezei M. Liposomes in the topical application of drugs: a review. In: Gregoriadis G, ed. Liposomes as Drug Carriers, Recent Trends and Progress, New York, NY: John Wiley and Sons; 1988.Google Scholar
  9. 19.
    Krowczynski L, Stozek T. Liposomes as drug-carriers in the transdermal therapy. Pharmazie. 1984;39:627–629.PubMedGoogle Scholar
  10. 10.
    Patel HM. Liposomes as a controlled-release system. Biochem Soc Trans. 1985;13:513–516.PubMedGoogle Scholar
  11. 11.
    Price CI, Horton JW, Baxter CR. Liposome delivery of aminoglycosides in burn wounds. Surg Gynecol Obstet. 1992;174:414–418.PubMedGoogle Scholar
  12. 12.
    Price CI, Horton JW, Baxter CR. Topical liposomal delivery of antibiotics in soft tissue infection. J Surg Res. 1990;49:174–178.PubMedCrossRefGoogle Scholar
  13. 13.
    Vyas SP, Singh R, Asati RK. Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. J Microencapsul. 1995;12:149–154.PubMedCrossRefGoogle Scholar
  14. 14.
    El-Ridy MS, Khalil RM. Free versus liposome-encapsulated lignocaine hydrochloride topical applications. Pharmazie. 1999;54:682–684.PubMedGoogle Scholar
  15. 15.
    Martin GP. Phospholipids as skin penetration enhancers. In: Walters KA, Hadgraft J, eds. Pharmaceutical Skin Penetration Enhancement. New York, NY: Marcel Dekker, 1993;57–60.Google Scholar
  16. 16.
    Yarosh DB. Topical application of liposomes. J Photochem Photobiol B. 1990;6:445–449.PubMedCrossRefGoogle Scholar
  17. 17.
    Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298:1015–1019.PubMedCrossRefGoogle Scholar
  18. 18.
    Nagarsenker MS, Londhe VY, Nadkarni GD. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm. 1999;190:63–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Elzainy AAW, Gu X, Simons FER, Simons KJ. Effect of different phospholipids on the stability of liposomal formulations containing hydroxyzine [abstract] AAPS Pharm Sci. 2002;4:4. Abstract R6110.Google Scholar
  20. 20.
    Olfert ED, Cross BM, Mcwilliam AA. Guide to the Care and Use of Experimental Animals. Ottawa ON, Canada: Canadian Council on Animal Care; 1993.Google Scholar
  21. 21.
    Simons FER, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic effects of the H1-receptor antagonist hydroxyzine. J Allergy Clin Immunol. 1984;73:69–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Watson WTA, Simons KJ, Chen XY, Simons FER. Cetirizine: a pharmacokinetics and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84:457–464.PubMedCrossRefGoogle Scholar
  23. 23.
    Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol. 2001;107:526–530.PubMedCrossRefGoogle Scholar
  24. 24.
    Balen GPV, Caron G, Ermondi G, Pagliara A, Grandi T, Bouchard G, Fruttero R, Carrupt P-A, Testa B. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res. 2001;18:694–701.CrossRefGoogle Scholar
  25. 25.
    Patel HM, Moghimi SM. Liposomes and the skin permeability barrier. In: Gregoriadis G, Florence AT, Patel HM, eds. Liposomes in Drug Delivery. Chur, Switzerland: Harwood Academic Publishers; 1993:142–146.Google Scholar
  26. 26.
    Mezei M, Liposomes and the skin. In: Gregoriadis G, Florence AT, Patel HM, eds. Liposomes in Drug Delivery. Chur, Switzerland: Harwood Academic Publishers; 1993;125–135.Google Scholar
  27. 27.
    Simons FER, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol. 2002;110:777–783.PubMedCrossRefGoogle Scholar
  28. 28.
    Rihoux JP. Therapeutic index of H1-antihistamines: example of cetirizine. Ann. Allergy Asthma Immunol. 1999;83:489–491.PubMedCrossRefGoogle Scholar
  29. 29.
    Foldvari M, Gesztes A, Mezei M. Dernal drug delivery by liposome encap sulation: clinical and electron microscopic studies. J Microencapsul. 1990;7:479–489.PubMedCrossRefGoogle Scholar
  30. 30.
    Bashir SJ, Maibach HI. Cutaneous metabolism during in-vitro percutaneous absorption. In: Bronaugh RL, Kraeling MEK, Yourick J, Hood HL, eds, Topical Absorption of Dermatological Products. New York, NY: Marcel Dekker, 2002;77–81.CrossRefGoogle Scholar
  31. 31.
    Wohlarb W, Lasch J. Penetration kinetics of liposomal hydrocortisone in human skin. Dermatologica. 1987;174:18–22.CrossRefGoogle Scholar
  32. 32.
    Wohlarb W, Lasch J. The effect of liposomal incorporation of topically applied hydrocortisone on its serum concentration and urinary excretion. Dermatol Monatsschr. 1989;175:348–352.Google Scholar
  33. 33.
    Mezei M, Gulasekharam V. Liposomes: a selective drug delivery system for the topical route of administration. 1. Lotion dosage form. Life Sci. 1980;26:1473–1477.PubMedCrossRefGoogle Scholar
  34. 34.
    Harsanyi BB, Hilchie JC, Mezei M. Liposomes as drug carriers for oral ulcers. J Dent Res. 1986;65:1133–1141.PubMedCrossRefGoogle Scholar
  35. 35.
    Foong WC, Harsany BB, Mezei M. Biodisposition and histological evaluation of topically applied retinoic acid in liposomal, cream and gel dosage forms. In: Hanin I, Pepeu G, eds. Phospholipids, New York, NY: Plenum Press; 1990:279–282.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2003

Authors and Affiliations

  • Abeer A W Elzainy
    • 1
  • Xiaochen Gu
    • 1
  • F. Estelle R. Simons
    • 2
  • Keith J. Simons
    • 1
    • 2
    Email author
  1. 1.Faculty of PharmacyUniversity of ManitobaWinnipegCanada
  2. 2.Department of Pediatrics and Child Health, Faculty of MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations